What is the lifetime maximum dose of doxorubicin?

The lifetime maximum dose of doxorubicin is typically set at 450-550 mg/m² for most patients. Doxorubicin is an anthracycline antibiotic that is widely used in cancer chemotherapy. One of its major concerns is cardiotoxicity, which can lead to heart damage and increase the risk of congestive heart failure, particularly when cumulative doses exceed the recommended limits.

The threshold of 450-550 mg/m² is established based on research indicating that doses above this range significantly increase the risk of severe cardiac complications. Monitoring cardiac function becomes crucial in patients receiving doxorubicin, particularly as they approach this cumulative dose limit. Doses beyond this range are reserved for special cases and must be approached with caution, often in combinations with cardioprotective agents if necessary.

Understanding this aspect of doxorubicin helps healthcare providers manage treatment plans effectively while minimizing the risk of long-term damage to the patient's heart.